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Abstract 
Background Iniparib is a novel anticancer agent initially considered a poly (ADP-ribose) 
polymerase (PARP) inhibitor, but subsequently shown to act via non-selective protein modification 
through cysteine adducts. This randomized phase II study investigated the addition of iniparib to 
gemcitabine–cisplatin in metastatic non-small-cell lung cancer (NSCLC) patients.  
Patients and methods Patients with histologically confirmed stage IV NSCLC were randomized 2 
: 1 to receive gemcitabine (1250 mg/m
2
, days 1/8) and cisplatin (75 mg/m
2
, day 1) with 
[gemcitabine/cisplatin/iniparib (GCI)] or without [gemcitabine/cisplatin (GC)] iniparib (5.6 mg/kg, 
days 1/4/8/11) every 3 weeks for six cycles. The primary end point was the overall response rate 
(ORR). Secondary objectives included progression-free survival (PFS), overall survival (OS), and 
safety. The study was not designed for formal efficacy comparison, the control arm being to 
benchmark results against the literature.  
Results One hundred and nineteen patients were randomized (39 GC and 80 GCI). More GCI 
patients were male (80% GCI and 67% GC) and had PS 0 (61% GCI and 49% GC). The ORR was 
25.6% [95% confidence interval (CI) 13.0%–42.1%] with GC versus 20.0% (95% CI 11.9%–
30.4%) with GCI, which did not allow rejection of the null hypothesis (ORR with GCI ≤20%; P = 
0.545). Median PFS was 4.3 (95% CI 2.8–5.6) months with GC and 5.7 (95% CI 4.6–6.6) months 
with GCI (hazard ratio 0.89, 95% CI 0.56–1.40). Median OS was 8.5 (95% CI 5.5 to not reached) 
months with GC, and 12.0 (95% CI 8.9–17.1) months with GCI (hazard ratio 0.78, 95% CI 0.48–
1.27). More GCI patients received second-line treatment (51% GC and 68% GCI). Toxicity was 
similar in the two arms. Grade 3–4 toxicities included asthenia (28% GC and 8% GCI), nausea (3% 
GC and 14% GCI), and decreased appetite (10% in each).  
Conclusions Addition of iniparib to GC did not improve ORR over GC alone. The GCI safety 
profile was comparable to GC alone. Imbalances in PS and gender distribution may have impacted 
study results regarding PFS and OS.  
Trial Registration ClinicalTrial.gov Identifier NCT01086254.  
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introduction 
Iniparib (4-iodo-3-nitrobenzamide, BSI-201) was originally investigated as a poly (ADP-ribose) 
polymerase (PARP) inhibitor. However, later preclinical studies showed that it does not possess 
typical characteristics of PARP inhibitors, instead inducing cell response by non-selective 
modification of numerous proteins via cysteine adducts [1]. It is believed that iniparib acts as a pro-
drug whose nitro-group is converted into either a nitroso-group or a nitrosyl radical by two 
alternative reduction processes. Proteomic and transcriptional profiling experiments and short-
hairpin RNA synergy screens are consistent with a mechanism, in which the Nrf2-mediated 
antioxidant response and/or the mitochondrial electron transport chain converts iniparib into its 
putative active metabolite. This metabolite was observed to uncouple electron transport from 
oxidative phosphorylation, leading to the production of reactive oxygen species at cytotoxic levels 
in an in vitro breast cancer model [2].  
Despite promising data from an earlier phase II study, the addition of iniparib to a gemcitabine–
carboplatin doublet failed to show a significant benefit in terms of the clinical benefit rate, overall 
response rate (ORR), progression-free survival (PFS), or overall survival (OS) in a phase III 
randomized study in metastatic triple-negative breast cancer patients [3, 4]. Iniparib administered 
either as a single agent or in combination with chemotherapy has shown a predictable and 
manageable safety profile at the proposed dose and schedule.  
Standard of care systemic therapy for inoperable non-small-cell lung cancer (NSCLC) is platinum-
based doublet chemotherapy. A survival benefit was reported in a meta-analysis comparing 
platinum agents combined with gemcitabine with other platinum doublets [5]. With a median OS of 
∼10 months in this population, additional therapeutic approaches are keenly awaited. The phase II 
study presented here investigated the potential benefit and safety of adding iniparib to the standard 
cisplatin (Bristol-Myers Squibb)–gemcitabine (Eli Lilly and Co) doublet for the treatment of 
metastatic NSCLC.  
patients and methods 
study design 
This phase II, randomized, open-label, non-comparative study was carried out in five European 
countries between May 2010 and December 2011. Patients were randomized to gemcitabine 1250 
mg/m
2
 (days 1 and 8) plus cisplatin 75 mg/m
2
 (day 1), with [gemcitabine/cisplatin/iniparib (GCI)] 
or without [gemcitabine/cisplatin (GC)] iniparib 5.6 mg/kg (1-h intravenous infusion, days 1, 4, 8, 
and 11) every 3 weeks for six cycles. A 2 : 1 randomization ratio in favor of GCI was used and 
randomization was stratified for histological type (squamous versus non-squamous) and smoking 
status (smoker versus never-smoker). Two dose reductions for gemcitabine or cisplatin were 
permitted for toxicity and a maximum 2-week treatment delay.  
Hematology, biochemistry, and vital signs were evaluated on days 1 and 8 of every cycle. Adverse 
events were graded according to NCI-CTCAE, v4.0. Tumor evaluation was carried out at screening 
and then every 6 weeks until progression, death, other anticancer treatment, or study cutoff date. 
After treatment, patients were followed up for survival every 3 months until cutoff. Response was 
evaluated by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST, 
v1.1). A confirmatory scan was carried out in patients with complete response (CR) or partial 
response (PR) at least 4 weeks after the initial documentation of response. The study was approved 
by the local and national ethics committee and conducted in accordance with the Declaration of 
Helsinki.  
patient eligibility 
Patients had to be at least 18 years old and have histologically confirmed, squamous or non-
squamous stage IV (UICC TNM 7th edition) NSCLC with no prior systemic therapy, measurable 
disease according to RECIST v1.1, an Eastern Cooperative Oncology Group (ECOG) performance 
status (PS) of 0 or 1, and adequate hematologic, renal, and hepatic function. Patients with prior 
definitive radiotherapy for locally advanced NSCLC were eligible. Patients with a history of cardiac 
disease or active brain metastases were not eligible. All patients gave written informed consent 
before enrollment.  
statistical analyses 
The study was not designed for formal comparisons of efficacy end points between arms, the 
control arm being used to benchmark results against available data for combined cisplatin–
gemcitabine. For the GCI arm, 70 patients were needed to provide ∼90% power to reject the null 
hypothesis that the true ORR with GCI was ≤20%, assuming the true response rate was 36%, using 
a one-sided exact binomial test at a significance level of 0.05. Thirty-five patients (50% of the GCI 
arm sample size) were planned in the control arm.  
The ORR with the 95% confidence interval (CI) was calculated in the intent to treat (ITT) 
population (i.e. all randomized patients). PFS was defined as the time from randomization to 
progressive disease (RECIST) or death, whichever was earlier. In the absence of progression or 
death, patients were censored at the last tumor assessment before cutoff or starting other anticancer 
therapy. OS was defined as the time from randomization to death. In the absence of death, patients 
were censored at the cutoff date or the last date they were alive, whichever was earlier. PFS and OS 
were analyzed with the Kaplan–Meier method. The cutoff date was 1 year after the first dose of the 
last treated patient. Safety data were summarized with descriptive statistics in patients who received 
at least one dose of study treatment.  
results 
A total of 119 patients were randomized, 39 to the GC arm, and 80 to the GCI arm. Two patients 
randomized to the GCI arm were not treated due to protocol deviations. Patient and disease baseline 
characteristics are summarized in Table 1. Characteristics were mostly well balanced between the 
two treatment arms, although more GCI patients were male (80% GCI and 67% GC) and had PS 0 
(61% GCI and 49% GC), while fewer GCI patients had an initial diagnosis of stage I or III (4% GCI 
and 10% GC). Median treatment duration was 13.9 weeks (range, 3–23 weeks) for the GC arm and 
15.0 weeks (range, 3–23 weeks) with GCI. A median number of four cycles was administered in 
both arms, and a similar proportion of patients in each arm completed the six planned treatment 
cycles (41% GC and 45% GCI). Median relative dose intensity was 88% and 85% for gemcitabine 
in the GC and GCI arms, respectively, 85% for cisplatin in both arms, and 91% for iniparib.  
Table 1.  
Patient and disease characteristics at study entry, ITT population 
antitumor activity 
The ORR in the ITT population was lower in the GCI arm than in the GC arm: 20.0% (95% CI 
11.9%– 30.4%) versus 25.6% (95% CI 13.0%– 42.1%), and did not allow rejection of the null 
hypothesis (ORR with GCI ≤20%; P = 0.545; Table 2). Best overall responses included 1 CR and 
15 PRs in the 80 GCI patients and 10 PRs in the 39 GC patients. Stable disease was more frequent 
in the GCI arm than in the GC arm (55% versus 44%, respectively).  
Table 2.  
Summary of efficacy parameters, ITT population 
survival 
At the cutoff date, progression or death was reported in 32 GC (82.1%) and 52 GCI patients 
(65.0%). Median PFS was 4.3 (95% CI 2.8–5.6) months in the GC arm and 5.7 (95% CI 4.6–6.6) 
months in the GCI arm, with a hazard ratio (HR) of 0.89 (95% CI 0.56–1.40) favoring the GCI arm 
(Figure 1A). Fourteen GC (35.9%) and 33 GCI patients (41.3%) were alive at last contact. Median 
OS was 12.0 (95% CI 8.9–17.1) months in the GCI arm and 8.5 (95% CI 5.5 to not reached) months 
in the GC arm, with an HR of 0.78 (95% CI 0.48–1.27; Figure 1B).  
 
Figure 1.  
Kaplan–Meier estimates of progression-free (A) and overall survival (B) in the ITT population, 
according to the treatment arm.  
safety 
Safety was analyzed in the 117 treated patients. Toxicity profiles were similar for the two arms 
(Table 3). Grade 1–2 hematologic toxicity was widespread, and approximately 50% of the patients 
had grade 3–4 events, notably neutropenia (44% GC and 37% GCI patients), including three GC 
patients with febrile neutropenia. Asthenia/fatigue and gastrointestinal toxicities were also frequent. 
Grade 3–4 toxicities included asthenia (28% GC and 8% GCI), nausea (3% GC and 14% GCI), 
decreased appetite (10% in both arms), vomiting and hypertension (8% in both arms), dyspnea 
(10% GC and 4% GCI), pulmonary embolism (8% GC and 6% GCI), and fatigue (5% in both 
arms). Differences between arms (including grade 3–4) were apparent for asthenia, nausea, 
dyspnea, hyponatremia, and febrile neutropenia, which were more frequent in GC patients, while 
pyrexia and abdominal pain were more common with GCI.  
Table 3.  
Main adverse events (NCI-CTCAE; >20% of patients and grade 3–4) and hematologic laboratory 
findings, safety population 
Five patients died due to adverse events, three of which were treatment-related (two GC patients, 
one with septic shock and the other with mental status changes, and cardiac failure in a GCI 
patient). Seven GC (18%) and 16 GCI (21%) patients discontinued the study due to a wide range of 
AEs (mostly grade 3–4). AEs led to dose reductions in 56% of the patients and delay in 
approximately one-third, generally due to hematologic toxicity or asthenia (Table 4). 
Approximately half of the patients had at least one gemcitabine or iniparib dose omission.  
Table 4.  
Treatment modifications 
therapy after GC or GCI treatment 
Second-line therapy was given at the investigator's discretion and could be started before 
documented progression. More than half of the patients received further systemic therapy on-study 
(51% GC and 68% GCI; Table 5), notably pemetrexed (GC 18% and GCI 20%) and docetaxel (GC 
18% and GCI 16%). In PFS analyses, more GCI patients were censored for initiating new antitumor 
therapy (22 patients, 27.5%) compared with GC (4 patients, 10.3%).  
Table 5.  
Therapy after GC or GCI treatment 
discussion 
Addition of iniparib to standard gemcitabine–cisplatin therapy did not improve the activity of this 
chemotherapy doublet in metastatic NSCLC patients in terms of the ORR (25.6%, 95% CI 13.0%–
42.1% with GC; 20.0%, 95% CI 11.9%–30.4% with GCI). The 25.6% ORR in the GC arm is close 
to the expected 28% rate [6], showing that patients enrolled in this study were representative of the 
targeted NSCLC population. The failure of iniparib to add clinical benefit in this context may be 
influenced by its mechanism of action which is different from that of PARP inhibitors [1]. Selection 
of PFS rather than ORR may have been a more appropriate end point for measuring benefit, the 
value of the latter having been questioned, notably in studies with targeted agents [7]. In addition, 
interpretation of the primary efficacy results may have been influenced by imbalances in various 
key baseline characteristics, such as PS, gender, and stage.  
For the secondary efficacy parameters, median PFS was longer in the GCI than in the GC arm (5.7 
versus 4.3 months, HR 0.89). However, median PFS in GC-treated patients was shorter than 
reported in phase III studies conducted in the same population (5.1–6.1 months) [6, 8–11]. 
Similarly, a marginal trend towards a survival benefit was seen with GCI (median OS of 12.0 versus 
8.5 months with GC alone, HR 0.78). Though here again median OS in GC-treated patients was 
shorter than published reports (9.6–12.5 months). Median OS in this small study may have been 
confounded by other factors such as subsequent therapy or tumor heterogeneity. To date, no 
pharmacodynamic markers predicting efficacy have been identified.  
The addition of iniparib did not significantly alter the GC safety profile, notably with respect to 
withdrawals due to toxicity, severe events, and reductions or delays for toxicity. Furthermore, most 
reported differences favored the GCI arm. Addition of iniparib did not impact the incidence of 
neutropenia or serious systemic infections, with no cases of febrile neutropenia in the GCI arm. The 
excess of severe asthenia/fatigue reported with GC may be due to the higher proportion of patients 
with PS 1 at baseline.  
This proof-of-concept study was not designed for formal comparison of efficacy end points between 
the test and the control arms. The purpose of the control arm was to benchmark results against 
historical data. However, due to the lack of efficacy of the test arm and since the patient population 
was representative of the studied disease, a single-arm trial design would have led to a similar 
conclusion.  
This trial enrolled patients approximately in parallel with a phase III study of gemcitabine and 
carboplatin with or without iniparib in patients with metastatic squamous NSCLC, the results of 
which were recently communicated as negative [12]. In conclusion, treatment of metastatic NSCLC 
patients with 5.6 mg/kg iniparib added to gemcitabine–cisplatin did not give benefit over the 
chemotherapy doublet alone, and no further clinical development of iniparib in this indication is 
planned.  
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